These data suggest that patients with mutBRAF melanoma survive longer than those with NRAS-mutant disease, but that the survival of mutBRAF melanoma is not different from that of melanoma patients with wtBRAF and wtNRAS. This evidence concerns the gene NRAS and melanoma.